

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
23523-0174

Total Pages in this Submission
69

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES

and invented by:

James M. Robl, Jose Cibelli and Amy Burnside

If ☒ **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 38 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications (if applicable)
 - c. ☒ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
23523-0174

Total Pages in this Submission
69

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☒ Formal b. ☐ Informal Number of Sheets 17
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
- ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☐ Genetic Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & documents)
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☐ Certificate of Mailing
- ☐ First Class ☐ Express Mail (Specify Label No.): _____

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
23523-0174

Total Pages in this Submission
69

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☒ Small Entity Statement(s) - Specify Number of Statements Submitted: 1

17. ☐ Additional Enclosures (please identify below):


Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	38	- 20 =	18	x \$9.00	\$162.00
Indep. Claims	4	- 3 =	1	x \$39.00	\$39.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$345.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$546.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1390** as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of **\$546.00** as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **October 27, 2000**


Signature

Samir Elamrani (Reg. No. 43,601)

**SHAW PITTMAN
2300 N Street, N.W.
Washington, D.C. 20037-1128
(202) 663-8000**

cc:

MA 99-15
Patent
Attorney's Docket No. 000270-083

Applicant or Patentee: James M. ROBL; Jose CIBELLI and Amy BURNSIDE
Application or Patent No.: 60/
Filed or Issued: October 28, 1999
For: GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 C.F.R. §§ 1.9(f) AND 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION University of Massachusetts, as represented by its Amherst Campus
ADDRESS OF ORGANIZATION Office of Vice Chancellor for Research at Amherst
Amherst, MA 01002

TYPE OF ORGANIZATION

- ☒ University or other institution of higher education
☐ Tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3))
☐ Nonprofit scientific or educational under statute of state of The United States of America
(Name of state _____)
(Citation of statute _____)
☐ Would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3)) if located in The United States of America
☐ Would qualify as nonprofit scientific or educational under statute of The United States of America if located in The United States of America
(Name of state _____)
(Citation of statute _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(a) for purposes of paying reduced fees under Sections 41(a) and 41(b) of Title 35, United States Code, with regard to the invention entitled GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES by inventor(s) James M. ROBL; Jose CIBELLI and Amy BURNSIDE described in

- ☐ the specification filed herewith
☒ Application No. 60/, filed October 28, 1999
☐ Patent No. _____, issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above-identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern, or organization having rights to the invention is listed below,* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an individual inventor under 37 C.F.R. § 1.9(c), or by any concern that would not qualify as either a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Application No. 89/
Attorney's Docket No. 000270-063

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27.)

FULL NAME _____

ADDRESS _____

☐ individual ☐ small business concern ☐ nonprofit organization

FULL NAME _____

ADDRESS _____

☐ individual ☐ small business concern ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee and any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b).)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Joseph F.X. McGuire

TITLE IN ORGANIZATION Executive Director, CVIP

ADDRESS OF PERSON SIGNING University of Massachusetts, 365 Plantation Street,

Suite 130, Worcester, MA 01605

SIGNATURE Joseph F.X. McGuire DATE October 28, 1999

**GYNOGENETIC OR ANDROGENETIC PRODUCTION
OF PLURIPOTENT CELLS AND CELL LINES, AND USE
THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES**

5

Government Rights

This invention was developed under a federally sponsored research project, *i.e.*, USDA Grant No. 97-35203-4905 and, therefore, the United States Government may have certain rights in the invention.

10

Cross Reference to Related Application

This Application claims priority from U.S. Provisional Application Serial No. 60/161,987 filed on October 28, 1999.

Field of the Invention

15

The present invention provides a novel method for producing pluripotent mammalian cell lines and differentiated cells, tissues and organs derived therefrom. Unlike previous reported methods for producing pluripotent cells, the subject pluripotent cells will be produced by gynogenetic or androgenetic means, *i.e.*, methods wherein the pluripotent cells are derived from oocytes containing only DNA of male or female origin and therefore will comprise all female-derived or male-derived DNA. In a preferred embodiment, the oocytes will comprise male or female-derived DNA of primate origin, *e.g.* human.

20

Background of the Invention

25

After ovulation, the oocytes of most mammals remain blocked at the second metaphase stage of meiosis and will eventually degenerate unless sperm penetration takes place. Sperm entry activates a whole series of events in the oocyte which leads to fertilization and the development of a new individual. The earliest changes that can be recognized in the oocyte during activation are the completion of meiosis with the omission of the second polar body and the release of the cortical granules. This is followed by the formation of the male and female pronuclei containing their respective haploid sets of chromosomes. A period of DNA synthesis occurs before the two sets of chromosomes condense and come together on the mitotic spindle of

30

002297-10200

However, it is also known that under certain conditions, which may occur spontaneously *in vivo*, or *in vitro*, under controlled conditions, that oocytes containing DNA of all male or female origin may be activated and result in the production of an embryo. Typically such embryo does not develop into an offspring, but rather stops developing fairly early in embryogenesis.

Parthenogenesis is a type of gynogenesis. Gynogenesis broadly is defined as the phenomena wherein an oocyte containing all female DNA becomes activated and produces an embryo. Gynogenesis includes parthenogenesis as well as activation methods wherein the spermatozoa activates the oocyte to complete meiosis, but fails to contribute any genetic material to the resulting embryo. As in parthenogenesis, the activated oocyte does not contain DNA of male origin. However, unlike parthenogenesis, however, the male gamete does make a contribution, i.e., it stimulates oocyte activation.

In general, embryos that result from oocytes containing DNA of all female or male origin only develop to a certain point, and then stop developing. This is hypothesized to occur, e.g., in the case of parthenogenetic embryos of the instability of the aging unfertilized oocyte in the maintenance of the meiotic block. In fact, parthenogenetically activated oocytes may give rise to a variety of aberrations that

occur during the completion of meiosis, which may result in the production of embryos of different genetic constitutions.

It is known that artificial activation of mammalian oocytes, including oocytes containing DNA of all male or female origin, can be induced by a wide variety of physical and chemical stimuli. Examples of such methods are listed in the Table below.

TABLE 1
List of physical and chemical stimuli which can induce oocyte activation in mammals.

Physical	Chemical
1. Mechanical (a) pricking (b) manipulation of oocytes <i>in vitro</i>	1. Enzymatic trypsin, pronase, hyaluronidase 2. Osmotic
2. Thermal (a) cooling (b) heating	3. Ionic (a) divalent cations (b) calcium ionophores
3. Electric	4. Anaesthetics (a) general - ether, ethanol, nembutal, chloroform, avertin (b) local - dibucaine, tetracaine, lignocaine, procaine 5. Phenothiazine, tranquillizers thioridazine, trifluoperazine, fluphenazine, chlorpromazine 6. Protein synthesis inhibitors cycloheximide, puromycin 7. Phosphorylation inhibitors (e.g., DMAP) 8. Inisitol 1,4,5-triphosphate (Ins P ₃)

Indeed, the activation of parthenogenetic oocytes has been well reported in the literature. For example, Ware et al, *Gamete Research*, 22:265-275 (1989) teach the

ability of bovine oocytes to undergo parthenogenetic activation using Ca^{++} , Mg^{++} - H^{+} ionophore (A23187) or electric shock. Also, Yang et al, *Soc. Study Reprod.*, 46:117 (1992) teaches activation of bovine follicular oocytes using cycloheximide and electric pulse treatment. Graham C. F. in *Biol. Rev.*, 49:399-422 (1979) describes then existing methods for activating parthenogenetic mammalian embryos. Further, Matthew H. Kaufman, in *Prog. in Anat.*, Vol. 1:1-34, ed. R. G. Harrison and R. L. Holmes, Cambridge Press, London, UK (1981) reviews parthenogenesis and methods of activation. The parthenogenetic activation of rabbit and mouse oocytes is also disclosed by Ozil, Jean Pierre, *Devel.*, 109:117-127 (1990); Kubiak, Jacek, *Devel. Biol.*, 136:537-545 (1989); Onodera et al, *Gamete Research*, 22:277-283 (1989); Siracusa et al, *J. Embryol. Exp. Morphol.*, 43:157-166 (1978); and Szollosi et al, *Chromosoma*, 100:339-354 (1991). Still further, the activation of unfertilized sea urchin eggs is disclosed by Steinhardt et al, *Nature*, 252:41-43 (1974); and Whitaker, M., *Nature*, 342:636-639 (1984). Also, the parthenogenetic activation of human oocytes has been reported. (See, e.g., De Sutter et al, *J. Associated Reprod. Genet.*, 9(4):328-336 (1992).)

In general, the goal of such artificial oocyte activation methods has been known in biological research, in particular the study of embryonic development, and the mechanisms which are involved in oocyte activation.

In recent years, a significant goal of many research groups has been the identification of methods that efficiently and reproducibly give rise to pluripotent or embryonic stem cells (ES cells), and ES or pluripotent cell lines. ES cells are extremely desirable because of their pluripotency which allows them to give rise to any differentiated cell type. Also, ES cells are useful for the production of chimeric animals and as an *in vitro* model for differentiation studies, especially the study of genes involved in early development.

Methods for deriving embryonic stem (ES) cell lines *in vitro* from early preimplantation mouse embryos are well known. (See, e.g., Evans et al., *Nature*, 29:154-156 (1981); Martin, *Proc. Natl. Acad. Sci., USA*, 78:7634-7638 (1981)). ES cells can be passaged in an undifferentiated state, provided that a feeder layer of

fibroblast cells (Evans et al., *Id.*) or a differentiation inhibiting source (Smith et al., *Dev. Biol.*, 121:1-9 (1987)) is present.

ES cells have been previously reported to possess numerous applications. For example, it has been reported that ES cells can be used as an *in vitro* model for
5 differentiation, especially for the study of genes which are involved in the regulation of early development. Mouse ES cells can give rise to germline chimeras when introduced into preimplantation mouse embryos, thus demonstrating their pluripotency (Bradley et al., *Nature*, 309:255-256 (1984)).

In view of their ability to transfer their genome to the next generation, ES cells
10 have potential utility for germline manipulation of livestock animals by using ES cells with or without a desired genetic modification. Moreover, in the case of livestock animals, e.g., ungulates, nuclei from like preimplantation livestock embryos support the development of enucleated oocytes to term (Smith et al., *Biol. Reprod.*, 40:1027-1035 (1989); and Keefer et al., *Biol. Reprod.*, 50:935-939 (1994)). This is in contrast
15 to nuclei from mouse embryos which beyond the eight-cell stage after transfer reportedly do not support the development of enucleated oocytes (Cheong et al, *Biol. Reprod.*, 48:958 (1993)). Therefore, ES cells from livestock animals are highly desirable because they may provide a potential source of totipotent donor nuclei, genetically manipulated or otherwise, for nuclear transfer procedures.

20 Some research groups have reported the isolation of purportedly pluripotent embryonic cell lines. For example, Notarianni et al., *J. Reprod. Fert. Suppl.*, 43:255-260 (1991), reports the establishment of purportedly stable, pluripotent cell lines from pig and sheep blastocysts which exhibit some morphological and growth characteristics similar to that of cells in primary cultures of inner cell masses isolated
25 immunosurgically from sheep blastocysts. Also, Notarianni et al., *J. Reprod. Fert. Suppl.*, 41:51-56 (1990) discloses maintenance and differentiation in culture of putative pluripotential embryonic cell lines from pig blastocysts. Gerfen et al., *Anim. Biotech*, 6(1):1-14 (1995) discloses the isolation of embryonic cell lines from porcine blastocysts. These cells are stably maintained in mouse embryonic fibroblast feeder

layers without the use of conditioned medium, and reportedly differentiate into several different cell types during culture.

Further, Saito et al., *Roux's Arch. Dev. Biol.*, 201:134-141 (1992) reports cultured, bovine embryonic stem cell-like cell lines which survived three passages, but were lost after the fourth passage. Handyside et al., *Roux's Arch. Dev. Biol.*, 196:185-190 (1987) discloses culturing of immunosurgically isolated inner cell masses of sheep embryos under conditions which allow for the isolation of mouse ES cell lines derived from mouse ICMs. Handyside et al. reports that under such conditions, the sheep ICMs attach, spread, and develop areas of both ES cell-like and endoderm-like cells, but that after prolonged culture only endoderm-like cells are evident.

Cherny et al., *Theriogenology*, 41:175 (1994) reported purportedly pluripotent bovine primordial germ cell-derived cell lines maintained in long-term culture. These cells, after approximately seven days in culture, produced ES-like colonies which stained positive for alkaline phosphatase (AP), exhibited the ability to form embryoid bodies, and spontaneously differentiated into at least two different cell types. These cells also reportedly expressed mRNA for the transcription factors OCT4, OCT6 and HES1, a pattern of homeobox genes which is believed to be expressed by ES cells exclusively.

Campbell et al., *Nature*, 380:64-68 (1996) reported the production of live lambs following nuclear transfer of cultured embryonic disc (ED) cells from day nine ovine embryos cultured under conditions which promote the isolation of ES cell lines in the mouse. The authors concluded that ED cells from day nine ovine embryos are totipotent by nuclear transfer and that totipotency is maintained in culture.

Van Stekelenburg-Hamers et al., *Mol. Reprod. Dev.*, 40:444-454 (1995), reported the isolation and characterization of purportedly permanent cell lines from inner cell mass cells of bovine blastocysts. The authors isolated and cultured ICMs from 8 or 9 day bovine blastocysts under different conditions to determine which feeder cells and culture media are most efficient in supporting the attachment and outgrowth of bovine ICM cells. They concluded that the attachment and outgrowth of

cultured ICM cells is enhanced by the use of STO (mouse fibroblast) feeder cells (instead of bovine uterus epithelial cells) and by the use of charcoal-stripped serum (rather than normal serum) to supplement the culture medium. Van Stekelenburg et al reported, however, that their cell lines resembled epithelial cells more than pluripotent ICM cells.

Smith et al., WO 94/24274, published October 27, 1994, Evans et al, WO 90/03432, published April 5, 1990, and Wheeler et al, WO 94/26889, published November 24, 1994, report the isolation, selection and propagation of animal stem cells which purportedly may be used to obtain transgenic animals. Evans et al. also reported the derivation of purportedly pluripotent embryonic stem cells from porcine and bovine species which assertedly are useful for the production of transgenic animals. Further, Wheeler et al, WO 94/26884, published November 24, 1994, disclosed purported embryonic stem cells which are assertedly useful for the manufacture of chimeric and transgenic ungulates. However, to the best of the inventors' knowledge, this work has never been reported in any peer-reviewed journal.

Quite recently, two research groups simultaneously reported the production of purified non-human primate and human ES cells. These ES cell lines were derived from non-human primate and human embryos. These purported ES cell lines were reported to be SSEA-1 negative, SSEA-4, and SEA-3 positive, TRA-1-60 and TR-A-1-81 positive, and alkaline phosphatase positive, to develop into all three embryonic germ layers (endoderm, mesoderm, ectoderm), to maintain a normal karyotype even after prolonged culturing, and to proliferate indefinitely *in vitro* in an undifferentiated state.

Also recently, a group of scientists at the University of Massachusetts and Advanced Cell Technology reported the production of a "human embryo" by cross species nuclear transplantation of human differentiated cells into a bovine oocyte, and the potential use thereof for the production of human ES cells. However, notwithstanding what has been reported, improved methods for obtaining ES cells, and methods for maintaining such cells *in vitro* for indefinite periods would be extremely useful.

Objects of the Invention

Therefore, it is an object of the invention to provide a novel method for producing pluripotent cells and cell lines, i.e., ES cells.

More specifically, it is an object of the invention to provide a method for
5 obtaining pluripotent cells or cell lines that comprise female-derived or male-derived DNA.

Still more specifically, it is an object of the invention to provide a method for obtaining pluripotent cells or cell lines that comprise primate female-derived or male-derived DNA, male or female DNA of human origin.

10 Related thereto, it is an object of the invention to provide pluripotent cells or cell lines that are isogenic to male or female donors, e.g., a human donor.

Also, it is an object of the invention to utilize pluripotent cells that comprise all female-derived or male-derived DNA for the production of differentiated cells, tissues and organs.

15 It is a related object of the invention to use pluripotent cells or cell lines, preferably human pluripotent cells or cell lines, to produce primate, preferably human, differentiated cells, tissues or organs by inducing differentiation of pluripotent cells or cell lines that comprise DNA of all male or female origin.

Further, it is an object of the invention to utilize pluripotent cells that comprise
20 all female-derived or male-derived DNA for the production of chimeric animals.

It is an even more specific object of the invention to produce pluripotent cells containing all male-derived or female-derived DNA by the following method:

- (I) producing a cell preferably in metaphase II, preferably an oocyte or blastomere that comprises all male- or female-derived DNA;
- 25 (ii) activating such oocyte or blastomere under conditions that (1) does not result in second polar body extrusion or (2) inhibits polar body extrusion, or (3) inhibits the first cleavage event; thereby producing an activated oocyte having a diploid content of DNA of male or female origin;
- (iii) culturing the resultant activated oocyte or blastomere under conditions
30 that give rise to an embryo comprising a trophectoderm and inner cell mass; and

(iv) culturing cells derived from said inner cell mass *in vitro* under conditions that maintain said cells in an undifferentiated, pluripotent state.

It is another more specific object of the invention to produce pluripotent cells containing all male-derived or female-derived DNA by the following method:

5 (i) transplanting an enucleated oocyte or blastomere with two haploid nuclei, both of either male or female origin;

(ii) activating said oocyte or blastomere;

(iii) culturing said activated oocyte or blastomere under conditions that result in an embryo comprising a trophectoderm and inner cell mass; and

10 (iv) culturing cells obtained from said inner cell mass *in vitro* under conditions that maintain said cells in an undifferentiated, pluripotent state.

It is another object of the invention to (I) produce embryos containing DNA of all male or female origin by any of the above-identified methods which contains a discernible inner cell mass and trophectoderm, (ii) selecting cells from said inner cell
15 mass or cells which have been isolated from said inner cell mass and cultured under conditions that maintain said cells in an undifferentiated, pluripotent state; and (iii) to confirm the pluripotency of such selected cells.

This can be effected by various methods, e.g., by testing for the presence of certain molecular markers that are characteristic of pluripotency; by making chimeric
20 animals using said cells and testing for the genetic contribution of said cells to the different cells of the chimeric animal by injection into SCID mice and observing the production of different differentiated cell types, and by observing the differentiation of such cells into embryoid bodies and other types of differentiated cells in tissue culture.

25 It is another object of the invention to provide a theoretically infinite supply of isogenic pluripotent cells by: (I) producing an embryo derived from all male or female DNA that contains a discernible trophectoderm and inner cell mass; (ii) culturing at least the inner cell mass of said embryo or a portion thereof under conditions that maintain said cells in a pluripotent undifferentiated state. This is
30 preferably effected by culturing the inner cell mass or a portion thereof under

conditions whereby such cells or inner cell mass is maintained in contact with a feeder layer, e.g., fetal fibroblasts. These cultured pluripotent cells will be transferred to new feeder layers as often as is required to maintain said cells in the desired pluripotent state.

5 Another object of the invention is to produce pluripotent cells that comprise a desired DNA modification. This will be effected by producing oocytes containing DNA of all male or female origin, wherein said DNA comprises a desired modification; activating said oocytes under conditions that give rise to an embryo having a discernible trophectoderm and inner cell mass; and culturing cells from said
10 inner cell mass or the entire cell mass under conditions that inhibit differentiation and maintain said cells in a pluripotent state that contain the desired DNA modification.

Still another object of the invention is to produce differentiated cells or tissues that contain a desired DNA modification comprising:

- (I) producing oocytes that contain DNA of all male or female origin,
15 which DNA comprises at least one modification;
- (ii) activating said oocytes under conditions that give rise to an embryo containing a discernible trophectoderm and inner cell mass;
- (iii) culturing at least said inner cell mass or a portion thereof under conditions that maintain said cells in an undifferentiated, pluripotent state; and
20 (iv) using said cultured cells to produce differentiated cells containing said at least one DNA modification. This can be effected, e.g., by altering the cell culture procedure, e.g., by addition of growth factors that promote differentiation; by removal of feeder layers, by injection into a suitable animal, e.g., SCID mouse, whereby differentiated cells and/or tissues arise from said cells *in vivo*; or by the use thereof to
25 produce a chimeric animal or fetus that contains differentiated cells that express the genotype of said male or female DNA, which comprises at least one DNA modification.

Still another object of the invention is to provide cell cultures comprising pluripotent cells which optionally may be genetically modified, wherein said

pluripotent cells are derived from embryos produced by androgenetic or gynogenetic methods.

Yet another object of the invention is to provide differentiated cells and tissues derived from pluripotent cells which are themselves derived from embryos produced
5 by androgenetic or gynogenetic methods.

Still another object of the invention is to use said pluripotent cells, or differentiated cells derived therefrom, which optionally may be genetically modified for cell and gene therapy, tissue and organ transplantation, or for the study of embryogenesis and differentiation. For example, the effect of specific DNA
10 modifications on embryonic development or the production of specific types of differentiated cells can be effected.

Yet another object of the invention is to culture pluripotent cells and cell lines produced according to the invention with different combinations of hormones, cytokines, and growth factors and ratios thereof that induce the differentiation of the
15 subject pluripotent cells into particular differentiated cell types.

It is yet another object of the invention to provide cloned animals, having a particular genotype, by use of pluripotent cells, or differentiated cells provided therefrom, produced according to the invention as nuclear donors for nuclear transfer.

It is still another object of the invention to utilize sperm or oocytes from
20 animals having desired characteristics, e.g. preferred agricultural characteristics, for the production of pluripotent cells and cell lines. These pluripotent cells or differentiated cells may be utilized as nuclear transfer donors.

It is another object of the invention to provide a novel business method for producing cloned agricultural animals having a desired genotype by sperm or oocytes
25 derived therefrom for use in the production of pluripotent cells or cell lines having the same genotype.

In a preferred object of the invention, the pluripotent cells or differentiated cells derived therefrom will be obtained by activation of an oocyte that contains only DNA of human male or human female origin, which DNA is optionally genetically
30 modified to produce an embryo containing a discernible trophectoderm and inner cells

mass, and wherein the inner cell mass or a portion thereof is cultured under conditions that maintain said cells in a pluripotent undifferentiated state; and which pluripotent cells give rise to differentiated cell types *in vivo* (e.g., in a SCID mouse), or when cultured under appropriate conditions.

5

Brief Description of the Drawings

Figure 1 (labeled 31-11): Embryoid body photographed at 100X magnification. Formed from explant plated directly on culture dish (no mouse fetal fibroblast feeder layer). Original colony (1023981-3) plated from a blastocyst activated previously. Light is deflected showing lipid content of cells.

Figure 2 (labeled 31-18): Embryoid body photographed at 100X magnification. Formed from explant plated directly on culture dish (no mouse fetal fibroblast feeder layer). Original colony (1023981-3) plated from a blastocyst activated a week prior.

Figure 3 (labeled 31-25): Embryoid body photographed at 100X magnification. Formed from explant plated directly on culture dish (no mouse fetal fibroblast feeder layer). Original colony (1023981-3) plated from a blastocyst activated week prior.

Figure 4 (labeled 32-1): Edge of explanted stem cell colony photographed at 40X magnification. Original colony (1023981-3) plated from blastocyst activated week prior. Stem cell colony is top left and mouse fetal fibroblast feeder layer is bottom right.

Figure 5 (labeled 32-3): Edge of explanted stem cell colony photographed at 100X magnification. Original colony (1023981-3) plated from blastocyst activated week prior. Stem cell colony is top left and mouse fetal fibroblast feeder layer is bottom right.

Figure 6 (labeled 32-5): Center of explanted stem cell colony photographed at 100X magnification. Original colony plated (1023981-3) from blastocyst activated week prior.

Figure 7 (labeled 32-12): Center of explanted stem cell colony photographed at 200X magnification. Original colony plated (1023981-3) from blastocyst activated week prior.

5 Figure 8 (labeled 35-6): Edge of explanted stem cell colony photographed at 40X magnification. Original colony (0106992-2) plated from blastocyst activated week prior. Stem cell colony is top right. Mouse fetal fibroblast feeder layer is bottom left. Light is deflected showing difference in lipid content between the cells of the stem cell colony and the mouse fibroblast feeder layer.

10 Figure 9 (labeled 35-8): Edge of explanted stem cell colony photographed at 40X magnification. Original colony (0106992-2) plated from blastocyst activated week prior. Stem cell colony is on the top. Mouse fetal fibroblast feeder layer is on the bottom. Light is deflected showing difference in lipid content between the cells of the stem cell colony and the mouse fibroblast feeder layer.

15 Figure 10 (labeled 35-19): Edge of explanted stem cell colony photographed at 200X magnification. Original colony (0106992-2) plated from blastocyst activated week prior. Stem cell colony is on the left. Mouse fetal fibroblast feeder layer is on the right. Photograph shows differentiation of the cells at the edge of the stem cell colony.

Figure 11 shows three monkey blastocysts on day 8 of development.

20 Figure 12 shows a cell line (Cyno 1) obtained from one of the three monkey blastocysts shown in Figure 11, before immunosurgery.

Figure 13 shows the Cyno 1 cell line after immunosurgery.

Figure 14 shows the Cyno 1 cell line 5 days after plating on a fibroblast feeder layer.

25 Figure 15 shows a pluripotent cell line (referred to as Cyno 1) derived from a parthenogenetically activated Cynomolgous monkey oocyte, growing on a mouse fibroblast layer. The feeder cells exhibit morphological characteristics of pluripotent cells, e.g. small nuclear cytoplasmic ratios and detectable cytoplasmic granules.

30 Figure 16 shows RT-PCR results demonstrating differentiation of multiple somatic cell types in differentiating PPSCs: Brachy: Brachyury (T) protein, MYH2:

Skeletal myosin Heavy Polypeptide 2, Enolase: Human neuron-specific Enolase 2,
SHH: Human homolog of Sonic Hedgehog.

Fig. 17 shows RT-PCR results using mRNA from monkey fibroblasts with or
without reverse transcriptase and PPSCs with or without reverse transcriptase. A
5 PCR product was detected of the predicted length only in the monkey fibroblasts
cells.

Detailed Description of the Invention

Prior to describing the invention in detail, the following terms are defined.

10 Otherwise, all terms in this application have their ordinary art-recognized meaning.

A. Definitions

Gynogenesis - in the present invention this refers to the production of an
embryo containing a discernible trophectoderm and inner cell mass that results upon
activation of a cell, preferably an oocyte, or other embryonic cell type, containing
15 mammalian DNA of all female origin, preferably human female origin, e.g., human or
non-human primate oocyte DNA. Such female mammalian DNA may be genetically
modified, e.g., by insertion, deletion or substitution of at least one DNA sequence, or
may be unmodified. For example, the DNA may be modified by the insertion or
deletion of desired coding sequences, or sequences that promote or inhibit
20 embryogenesis. Typically, such embryo will be obtained by *in vitro* activation of an
oocyte that contains DNA of all female origin. Gynogenesis is inclusive of
parthenogenesis which is defined below. It also includes activation methods wherein
the sperm or a factor derived therefrom initiates or participates in activation, but the
spermatozoal DNA does not contribute to the DNA in the activated oocyte.

25 Androgenesis - in the present invention this refers to the production of an
embryo containing a discernible trophectoderm and inner cell mass that results upon
activation of an oocyte or other embryonic cell type, e.g., blastomere, that contains
DNA of all male origin, e.g., human spermatozoal DNA. Optionally, said DNA of all
male origin may be genetically modified, e.g., by the addition, deletion, or

substitution of at least one DNA sequence (as described above with respect to gynogenesis).

Parthenogenesis - the process by which activation of the oocyte occurs in the absence of sperm penetration. In the present invention, parthenogenesis refers to the development of an early stage embryo comprising trophectoderm and inner cell mass
5 that is obtained by activation of an oocyte or embryonic cell, e.g., blastomere, comprising DNA of all female origin.

Pluripotent cell - in the present invention this refers to a cell derived from a embryo produced by activation of a cell containing DNA of all female or male origin that can be maintained *in vitro* for prolonged, theoretically indefinite period of time in
10 an undifferentiated state, that can give rise to different differentiated tissue types, i.e., ectoderm, mesoderm, and endoderm. The pluripotent state of said cells is preferably maintained by culturing inner cell mass or cells derived from the inner cell mass of an embryo produced by androgenetic or gynogenetic methods under appropriate conditions, preferably by culturing on a fibroblast feeder layer or another feeder layer
15 or culture that includes leukemia inhibitory factor. The pluripotent state of such cultured cells can be confirmed by various methods, e.g., (i) confirming the expression of markers characteristic of pluripotent cells; (ii) production of chimeric animals that contain cells that express the genotype of said pluripotent cells; (iii) injection of cells into animals, e.g., SCID mice, with the production of different
20 differentiated cell types *in vivo*; and (iv) observation of the differentiation of said cells (e.g., when cultured in the absence of feeder layer or LIF) into embryoid bodies and other differentiated cell types *in vitro*.

Diploid cell - in the present invention, this typically refers to a cell, e.g., an oocyte or blastomere, having a diploid DNA content of all male or female origin.

25 Haploid cell - in the present invention, this typically refers to a cell, e.g., an oocyte or blastomere having a haploid DNA content, wherein the haploid DNA is of all male or female origin.

Activation - process wherein fertilized or unfertilized oocyte, preferably in metaphase II of meiosis undergoes a process typically including separation of the
30 chromatid pairs, extrusion of the second polar body, resulting in an oocyte having a

haploid number of chromosomes, each with one chromatid. In the present invention, activation refers to methods whereby a cell containing DNA of all male or female origin is induced to develop into an embryo that has a discernible inner cell mass and trophectoderm, which is useful for producing pluripotent cells but which is itself
5 incapable of developing into a viable offspring. Preferably, in the present invention, activation is preferably effected under one of the following conditions: (i) conditions that do not cause second polar body extrusion; (ii) conditions that cause polar body extrusion but wherein polar body extrusion is inhibited; or (iii) conditions that inhibit first cell division of haploid oocyte. Also, the present invention includes activation of
10 oocytes or blastomeres that have been transplanted with two male or two female haploid nuclei.

Metaphase II - stage of cell development wherein the DNA content of a cell consists of a haploid number of chromosomes with each chromosome represented by two chromatids.

15 Embryo - in the present invention this typically refers to an embryo that results upon activation of a cell, e.g., oocyte or other embryonic cells containing DNA of all male or female origin, which optionally may be modified, that comprises a discernible trophectoderm and inner cell mass, which cannot give rise to a viable offspring and wherein the DNA is of all male or female origin. The inner cell mass or cells
20 contained therein are useful for the production of pluripotent cells as defined previously.

Inner cell mass - inner portion of an embryo which gives rise to fetal tissues. Herein, these cells are used to provide a continuous source of pluripotent cells *in vitro*. In the present invention, the inner cell mass refers to the inner portion of the
25 embryo that results from androgenesis or gynogenesis, i.e., embryos that result upon activation of cells containing DNA of all male or female origin. Preferably, such DNA will be human DNA, e.g., human oocyte or spermatozoal DNA, which optionally has been genetically modified.

Trophectoderm - other portion of early stage embryo which gives rise to
30 placental tissues. In the present invention, the trophectoderm is that of an embryo that

results from androgenesis or gynogenesis, i.e., embryos that result from activation of cells that contain DNA of all male or female origin, e.g., human oocyte or spermatozoan.

Differentiated cell - a non-embryonic cell that possesses a particular
5 differentiated, i.e., non-embryonic state. The three earliest differentiated cell types are endoderm, mesoderm and ectoderm.

B. Detailed Description

The present invention provides novel methods for obtaining pluripotent cells and cell lines, wherein the DNA is derived from a single individual, i.e., male or
10 female, by androgenesis or gynogenesis.

In the native environment, immature oocytes (eggs) from the ovary undergo a process of maturation which results in the progression through meiosis to metaphase II of meiosis. The oocytes then arrest at metaphase II. In metaphase II, the DNA content of the cell consists of a haploid number of chromosomes, each represented by
15 two chromatids.

Normally, the oocyte is ovulated at this stage and fertilized by the sperm. The sperm initiates the completion of meiosis in a process called activation. During activation, the pairs of chromatids separate, the second polar body is extruded, and the oocyte retains a haploid number of chromosomes, each with one chromatid. The
20 sperm contributes the other haploid complement of chromosomes to make a full diploid cell with single chromatids. The chromosomes then progress through DNA synthesis during the first cell cycle. These cells then develop into embryos.

By contrast, in the present invention, embryos are developed by artificial activation of cells, typically mammalian oocytes or blastomeres containing DNA of
25 all male or female origin. As discussed in the background of the invention, many methods have been reported in the literature for artificial activation of unfertilized oocytes. Such methods include physical methods, e.g., mechanical methods such as pricking, manipulation or oocytes in culture, thermal methods such as cooling and heating, repeated electric pulses, enzymatic treatments, such as trypsin, pronase,
30 hyaluronidase, osmotic treatments, ionic treatments such as with divalent cations and

calcium ionophores, the use of anaesthetics such as ether, ethanol, tetracaine, lignocaine, procaine, phenothiazine, tranquilizers such as thioridazine, trifluoperazine, fluphenazine, chlorpromazine, the use of protein synthesis inhibitors such as cycloheximide, puromycin, the use of phosphorylation inhibitors, e.g., protein kinase inhibitors such as DMAP, combinations thereof, as well as other methods.

Such activation methods are well known in the art and are discussed in our earlier patent application, U.S. Serial No. 08/781,752, now U.S. Patent No. 5,945,577. This application is incorporated by reference in its entirety herein.

In the present invention, a mammalian cell, preferably in metaphase II, typically an oocyte or blastomere comprising DNA of all male or female origin is artificially activated by a known means for effecting artificial activation of oocytes or nuclear transfer fusions. Dependent upon the activation procedure, the cell may extrude the second polar body or retain the second polar body.

In one embodiment of the present invention, a mammalian cell, preferably in metaphase II, e.g., a mammalian oocyte containing haploid content of DNA of all male or female origin is activated by an activation procedure that does not result in second polar body extrusion. This can be effected by various methods including the use of a phosphorylation inhibitor such as DMAP or by use of a microfilament inhibitor such as cytochalasin B, C or D, or a combination thereof. Thereby, cells are obtained having a diploid content of DNA of either male or female origin which develop into an embryo having a discernible trophectoderm and inner cell mass which will not give rise to viable offspring. The inner cell mass or cells therein are used to produce pluripotent cells containing cultures which are themselves useful for making differentiated cells and tissues.

In a second embodiment of the invention, a haploid cell, preferably in metaphase II, typically an oocyte or blastomere that comprises all male or female DNA, will be activated under conditions that result in the production of an embryo having a discernible trophectoderm and inner cell mass, but wherein the first cleavage event is prevented, thereby resulting in a diploid cell which develops into an embryo that cannot give rise to an offspring.

Still alternatively, the invention includes the embodiment wherein an enucleated cell, e.g., mammalian oocyte or blastomere, or other mammalian cytoplasm, is transplanted with two male or female haploid nuclei, e.g., derived from oocytes or sperm, and is activated by an appropriate activation procedure to produce an embryo
5 containing a discernible trophectoderm and inner cell mass which is incapable of giving rise to an offspring. Again, the inner cell mass or cells derived therefrom are useful for obtaining pluripotent cells which may be maintained for prolonged periods in tissue culture.

In all cases, the activated cell, e.g., oocyte, which is diploid, is allowed to
10 develop into an embryo that comprises a trophectoderm and an inner cell mass. This can be effected using known methods and culture media that facilitate blastocyst development. Examples thereof are disclosed in our earlier patent application, U.S. Patent No. 5,945,577, and have been well reported in the literature. Culture media suitable for culturing and maturation of embryos are well known and include Ham's
15 F-10 +10% fetal calf serum, Tissue Culture Medium, 199 (TCM-199) + 10% fetal calf serum, Tyrodes - Albumin - Lactate - Pyruvate (TALP), Dulbecco's Phosphate Buffered Saline (PBS), Eagles and Whitten's media, and CR1 medium. A preferred medium is for bovine embryos TCM-199 with Earl salts, 10% fetal calf serum, 0.2 mM Na pyruvate and 50 μ g/ml gentamycin sulfate. A preferred medium for culturing
20 pig embryos is NCSU23.

Preferred medium for culturing primate embryos, e.g., human and non-human primate embryos, include modified Ham's F-10 medium (Gibco, Catalog No. 430-1200 EB) supplemented with 1 ml/L synthetic serum replacement (SSR-2, Mediatech, Denmark), and 10 mg/ml HSA; 80% Dulbecco's modified Eagle's medium (DMEA,
25 no pyruvate, high glucose formulation, Gibco BRL) with 20% fetal bovine serum, 0.1 mM B-mercaptoethanol, and 1% non-essential amino acid stock, and by methods and medium disclosed in Jones et al, *Human Reprod.* 13(1):169-177 (1998); Thomson et al, *Proc. Natl. Acad. Sci., USA*, 92:7894-7898 (1995); and Thomson et al, *Science*, 282:1145-1147 (1998); and two media available from Irvine Scientific, Santa Anna,

California, i.e., a first media called P-1 (Cat. #99242) which is used for the first three days of culture followed by a second media, P-2 (Cat. #99292) until blastocyst stage.

Suitable activation conditions for human oocytes which may be applicable herein include the following:

5 1. *Activation by Ionomycin and DMAP*

 (i)

- a. Place oocytes in Ionomycin (5 μ M) with 2 mM of DMAP for
 four minutes.
- b. Move the oocytes into culture media with 2 mM of DMAP for
10 four hours.
- c. Rinse four times and place in culture.

 (ii)

- a. Place oocytes 22 to 28 hours post-maturation in 2mM of
15 DMAP.
- b. After one hour, transfer to 5 μ M of ionomycin.
- c. After 3 to 5 minutes, transfer and incubate in 5 μ g/ml of
 cytochalasm B and 10 μ g/ml of cycloheximide for eight hours.

20 2. **Activation by Ionomycin DMAP and Roscovitin**

- a. Place oocytes in Ionomycin (5 μ m) with 2 mM of DMAP for
 four minutes.
- b. Move the oocytes into culture media with 2 mM of DMAP and
 200 microM of Roscovitin for three hours.

- 25 c. Rinse four times and place in culture.

 3. **Activation by exposure to Ionomycin followed by cytochalasin and
 cycloheximide.**

- 30 a. Place oocytes in Ionomycin (5 microM) for four minutes.

- b. Move oocytes to culture media containing 5 $\mu\text{g/ml}$ of cytochalasin B and 5 $\mu\text{g/ml}$ of cycloheximide for five hours.
- c. Rinse four times and place in culture.

10

15

Activation by microinjection of adenophostin

20

25

30

8. Activation by microinjection of recombinant sperm factor

After the androgenetic or gynogenetic embryos have been cultured to produce a discernable trophectoderm and inner cell mass, the cells of the inner cell mass are then used to produce the desired pluripotent cell lines. This can be accomplished by transferring cells derived from the inner cell mass or the entire inner cell mass onto a culture that inhibits differentiation. This is preferably effected by transferring said
5 inner cell mass cells onto a feeder layer that inhibits differentiation, e.g., fibroblasts or epithelial cells, such as fibroblasts derived from murines, ungulates, chickens, such as mouse or rat fibroblasts, 570 and SI-m220 feeder cells, BRL cells, etc., or other cells that produce LIF. Preferably, the inner cell mass cells are cultured on mouse fetal
10 fibroblast cells or other cells which produce leukemia inhibitory factor, or in the presence of leukemia inhibitory factor. Culturing will be effected under conditions that maintain said cells in an undifferentiated, pluripotent state, for prolonged periods, theoretically indefinitely.

Suitable conditions for culturing pluripotent cells, specifically pluripotent cells
15 derived from ungulate inner cell mass are also described in our earlier patent U.S. Patent No. 5,945,577, as well as U.S. Patent No. 5,905,042, both of which are incorporated by reference herein in their entirety.

As noted, the subject invention will give rise to pluripotent cells having DNA that is exclusively of male or female origin, which may be used to produce different
20 differentiated cell types.

In a preferred embodiment, such exclusively male or female DNA will be genetically modified before or after activation of the cell containing same, e.g., human oocyte.

Methods and materials for effecting genetic modification are well known and
25 include microinjection, the use of viral DNAs, homologous recombination, etc. Thereby, pluripotent cells are obtained that comprise a desired DNA modification, e.g., contain a desired coding sequence.

The novelty of the invention is in the production of pluripotent cells that contain either female- or male-derived DNA. To the inventors' knowledge, this has
30 not been reported for any species. Considerable work has been done in the mouse

with pluripotent and totipotent embryonic stem cells but these have all been derived from either normal embryonic cells or primordial germ cells. Each of these cell types has both paternal and maternal DNA. Work has also been done with embryos containing either male-derived or female-derived DNA. These studies indicate that for full development of an embryo to term the cells must contain both male- and female-derived DNA. Imprinting of the DNA during meiosis results in some chromosomal segments being inactivated. Interestingly, if the cells are combined with normal embryonic cells in a chimera they do have the ability to form all the various cell types in the body. What has not been done for any species is the derivation of pluripotent cell lines containing only female- or male-derived DNA. Furthermore, no one has shown that these cells are capable of differentiation in culture.

An important feature of these cells is they would be immunologically similar, although not identical to the individual from which the DNA came. Consequently, they would also be the most immunologically compatible cells that could be obtained from an individual without the use of cloning. Furthermore, they would not generate the ethical concerns that the use of a normal embryo would generate because they could contain DNA from a single individual and would not be capable of forming an offspring.

However, another contemplated application of these cells and cell lines and differentiated cells derived therefrom is as donor cells for nuclear transfer, e.g. by the methods reported in U.S. Patent 5,945,577 or patents and patent applications by the Roslin Institute. Essentially, these methods differ in that the ACT cloning methods utilize proliferating donor cells, e.g. mammalian somatic cells, such as fibroblasts, whereas the Roslin Institute methods utilize quiescent donor cells.

The pluripotent state of the cells produced by the present invention can be confirmed by various methods.

For example, the cells can be tested for the presence or absence of characteristic ES cell markers. In the case of human ES cells, examples of such

markers are identified *supra*, and include SSEA-4, SSEA-3, TRA-1-60 and TRA-1-81 and are known in the art.

Also, pluripotency can be confirmed by injecting the cells into a suitable animal, e.g., a SCID mouse, and observing the production of differentiated cells and tissues. Still another method of confirming pluripotency is using the subject pluripotent cells to generate chimeric animals and observing the contribution of the introduced cells to different cell types. Methods for producing chimeric animals are well known in the art and are described in our related applications, incorporated by reference herein.

Yet another method of culturing pluripotency is to observe their differentiation into embryoid bodies and other differentiated cell types when cultured under conditions that favor differentiation (e.g., removal of fibroblast feeder layers). This method has been utilized in the present invention and it has been confirmed that the subject pluripotent cells give rise to embryoid bodies and different differentiated cell types in tissue culture. For example, it has been shown that Cynomolgous pluripotent cell lines produced herein give rise to beating cardiomyocytes and other cells when allowed to differentiate by culturing of the cell line beyond confluency.

The resultant pluripotent cells and cell lines, preferably human pluripotent cells and cell lines, which are derived from DNA of entirely male or female original, have numerous therapeutic and diagnostic applications. Most especially, such pluripotent cells may be used for cell transplantation therapies or gene therapy (if genetically modified). Human ES cells have application in the treatment of numerous disease conditions.

In this regard, it is known that mouse embryonic stem (ES) cells are capable of differentiating into almost any cell type, e.g., hematopoietic stem cells. Therefore, human or other mammalian pluripotent (ES) cells produced according to the invention should possess similar differentiation capacity. The pluripotent cells according to the invention will be induced to differentiate to obtain the desired cell types according to known methods. For example, human ES cells produced according to the invention may be induced to differentiate into hematopoietic stem cells, muscle cells, cardiac

muscle cells, liver cells, cartilage cells, epithelial cells, urinary tract cells, etc., by culturing such cells in differentiation medium and under conditions which provide for cell differentiation. Medium and methods which result in the differentiation of ES cells are known in the art as are suitable culturing conditions.

5 For example, Palacios et al, *Proc. Natl. Acad. Sci., USA*, 92:7530-7537 (1995) teaches the production of hematopoietic stem cells from an embryonic cell line by subjecting stem cells to an induction procedure comprising initially culturing aggregates of such cells in a suspension culture medium lacking retinoic acid followed by culturing in the same medium containing retinoic acid, followed by
10 transferral of cell aggregates to a substrate which provides for cell attachment.

Moreover, Pedersen, *J. Reprod. Fertil. Dev.*, 6:543-552 (1994) is a review article which references numerous articles disclosing methods for *in vitro* differentiation of embryonic stem cells to produce various differentiated cell types including hematopoietic cells, muscle, cardiac muscle, nerve cells, among others.

15 Further, Bain et al, *Dev. Biol.*, 168:342-357 (1995) teaches *in vitro* differentiation of embryonic stem cells to produce neural cells which possess neuronal properties. These references are exemplary of reported methods for obtaining differentiated cells from embryonic or stem cells. These references and in particular the disclosures therein relating to methods for differentiating embryonic stem cells are
20 incorporated by reference in their entirety herein.

Thus, using known methods and culture medium, one skilled in the art may culture the subject ES cells, including genetically engineered or transgenic ES cells, to obtain desired differentiated cell types, e.g., neural cells, muscle cells, hematopoietic cells, etc.

25 Pluripotent cells produced by the invention may be used to obtain any desired differentiated cell type. Therapeutic usages of differentiated human cells are unparalleled. For example, human hematopoietic stem cells may be used in medical treatments requiring bone marrow transplantation. Such procedures are used to treat many diseases, e.g., late stage cancers such as ovarian cancer and leukemia, as well as
30 diseases that compromise the immune system, such as AIDS. Hematopoietic stem

cells can be obtained, e.g., by incorporating male or female DNA derived from a male or female cancer or AIDS patient with an enucleated oocyte, obtaining pluripotent cells as described above, and culturing such cells under conditions which favor differentiation, until hematopoietic stem cells are obtained. Such hematopoietic cells
5 may be used in the treatment of diseases including cancer and AIDS.

Alternatively, the subject pluripotent cells may be used to treat a patient with a neurological disorder by culturing such cells under differentiation conditions that produce neural cell lines. Specific diseases treatable by transplantation of such human neural cells include, by way of example, Parkinson's disease, Alzheimer's disease,
10 ALS and cerebral palsy, among others. In the specific case of Parkinson's disease, it has been demonstrated that transplanted fetal brain neural cells make the proper connections with surrounding cells and produce dopamine. This can result in long-term reversal of Parkinson's disease symptoms.

The great advantage of the subject invention is that it provides an essentially
15 limitless supply of pluripotent, preferably pluripotent human cells that can be used to produce differentiated cells suitable for transplantation. Such cells should alleviate the significant problem associated with current transplantation methods, i.e., rejection of the transplanted tissue which may occur because of host-vs-graft or graft-vs-host rejection. Conventionally, rejection is prevented or reduced by the administration of
20 anti-rejection drugs such as cyclosporin. However, such drugs have significant adverse side-effects, e.g., immunosuppression, carcinogenic properties, as well as being very expensive. The present invention should eliminate, or at least greatly reduce, the need for anti-rejection drugs.

Other diseases and conditions treatable by cell therapy include, by way of
25 example, spinal cord injuries, multiple sclerosis, muscular dystrophy, diabetes, liver diseases, i.e., hypercholesterolemia, heart diseases, cartilage replacement, burns, foot ulcers, gastrointestinal diseases, vascular diseases, kidney disease, urinary tract disease, and aging related diseases and conditions.

This methodology can be used to replace defective genes, e.g., defective
30 immune system genes, cystic fibrosis genes, or to introduce genes which result in the

expression of therapeutically beneficial proteins such as growth factors, lymphokines, cytokines, enzymes, etc. For example, the gene encoding brain derived growth factor may be introduced into human pluripotent cells produced according to the invention, the cells differentiated into neural cells and the cells transplanted into a Parkinson's
5 patient to retard the loss of neural cells during such disease.

Previously, cell types transfected with BDNF varied from primary cells to immortalized cell lines, either neural or non-neural (myoblast and fibroblast) derived cells. For example, astrocytes have been transfected with BDNF gene using retroviral vectors, and the cells grafted into a rat model of Parkinson's disease (Yoshimoto et al.,
10 *Brain Research*, 691:25-36, (1995)).

This *ex vivo* therapy reduced Parkinson's-like symptoms in the rats up to 45% 32 days after transfer. Also, the tyrosine hydroxylase gene has been placed into astrocytes with similar results (Lundberg et al., *Develop. Neurol.*, 139:39-53 (1996) and references cited therein).

15 However, such *ex vivo* systems have problems. In particular, retroviral vectors currently used are down-regulated *in vivo* and the transgene is only transiently expressed (review by Mulligan, *Science*, 260:926-932 (1993)). Also, such studies used primary cells, astrocytes, which have finite life span and replicate slowly. Such properties adversely affect the rate of transfection and impede selection of stably
20 transfected cells. Moreover, it is almost impossible to propagate a large population of gene targeted primary cells to be used in homologous recombination techniques. By contrast, the difficulties associated with retroviral systems should be eliminated by the use of the methods herein.

Genes which may be introduced into the subject pluripotent cells include, by
25 way of example, epidermal growth factor, basic fibroblast growth factor, glial derived neurotrophic growth factor, insulin-like growth factor (I and II), neurotrophin-3, neurotrophin-4/5, ciliary neurotrophic factor, AFT-1, cytokine genes (interleukins, interferons, colony stimulating factors, tumor necrosis factors (alpha and beta), etc.), genes encoding therapeutic enzymes, etc.

In addition to the use of human pluripotent cells and cells derived therefrom in cell, tissue and organ transplantation, the present invention also includes the use of non-human cells in the treatment of human diseases. For example, non-human primate pluripotent cells produced according to the invention should be useful for treatment of human disease conditions where cell, tissue or organ transplantation is warranted (given the phylogenetic closeness of primates and humans (immunogenicity should be less of a concern.) In general, pluripotent cells and differentiated cells derived therefrom produced according to the present invention can be used within the same species (autologous, syngenic or allografts) or across species (xenografts). For example, brain cells derived from bovine or porcine pluripotent cells may be used to treat Parkinson's disease.

Also, the subject pluripotent ES cells, preferably human cells, may be used as an *in vitro* model of differentiation, in particular for the study of genes which are involved in the regulation of early development. Also, differentiated cell tissues and organs produced using the subject ES cells may be used in drug studies.

Further, the subject ES cells or differentiated cells derived therefrom may be used as nuclear donors for the production of other ES cells and cell colonies, or in the case of non-human cells, for the production of cloned animals.

Still further, pluripotent cells obtained according to the invention may be used to identify proteins and genes that are involved in embryogenesis. This can be effected e.g. by differential expression, i.e. by comparing mRNA's that are expressed in pluripotent cells provided according to the invention to mRNAs that are expressed as these cells differentiate in to different cell types, e.g., neural cells, myocardiocytes, other muscle cells, skin cells, etc. Thereby, it may be possible to determine what genes are involved in differentiation of specific cell types.

Also, it is another object of the invention to expose pluripotent cell lines produced according to the invention to cocktails of different growth factors, at different concentrations so as to identify conditions that induce the production and proliferation of desired differentiated cell types.

In order to more clearly describe the subject invention, the following example is provided.

EXAMPLE 1

**Production of Pluripotent Cells by Activation of Bovine
Oocytes Containing DNA of Female Origin**

The example describes one method of producing pluripotent cells by androgenetic or gynogenetic activation and production of embryos. In particular, this example describes the production of pluripotent cells from parthenogenetically activated bovine oocytes (gynogenetic activation of bovine oocytes containing all female DNA effected using ionomycin and DMAP). As described below, and substantiated by Figures 1 through 10, this procedure resulted in the production of an embryo having a discernible trophectoderm and inner cell mass, the inner cell mass of which, when cultured on a mouse fetal fibroblast feeder layer gave rise to pluripotent cells which produce differentiated cells (*See especially Figure 10*).

Materials and Methods Used in Example
Media and Solutions

20	Hyaluronidase (0.01% solution)		
	Hyaluronidase	(Sigma H-3506)	1 mg
	DPBS		1 ml

TL Hepes		
	NaCNaCl	(Sigma S-5886) 666 mg
	KCl	(Sigma P-5404) 24 mg
	NaHCO ₃	(Sigma S-5761) 16.8 mg
5	NaH ₂ PO ₄ -H ₂ O	(Sigma S-9638) 4.76 mg
	Hepes	(Sigma H-9136) 240 mg
	Na Lactate (60% syrup)	(Sigma L-1375) 186 μ l
	Phenol Red (0.5% solution)	(Sigma P-0290) 100 μ l
	CaCl ₂ -2H ₂ O	(Sigma C-7902) 300 mg
10	MgCl ₂ 6H ₂ O	(Sigma M-2393) 5 mg
	Embryo transfer H ₂ O	(Sigma W-1503) enough to make final volume 100 ml

- Adjust pH to 7.3-7.4
- Filter with 0.2 μ m filter and place in 50 ml capped bottle, label and date.
- Store buffer at 4°C

15

002207-2626990

HECM Hepes		
NaCl	(Sigma S-5886)	0.662 g
KCl	(Sigma P-5405)	0.0239 g
CaCl ₂ -2H ₂ O	(Sigma C-7902)	0.0294 g
5 MgCl ₂ -6H ₂ O	(Sigma M-2393)	0.0102 g
BME-ammino acids	(Sigma B-6766)	1 ml
Na Lactate	(Sigma L-1375)	1.4 ml
Na Pyruvate	(Sigma P-2256)	0.011 g
NaHCO ₃	(Sigma S-5761)	0.168 g
10 Hepes	(Sigma H-9136)	0.238 g
Phenol Red	(Sigma P-0290)	0.1 ml
Pen/Strep	(Sigma P-3539)	1 ml
BSA fraction V	(Sigma A-4503)	0.3 g
Embryo transfer H ₂ O	(Sigma W-1503)	enough to make final volume 100 ml

- 15
- Osmolarity must be 275 +/- 10 mOsm/kg
 - Adjust pH to 7.3-7.4
 - Filter with 0.2 μ m filter and place in 50 ml capped bottle, label and date.
 - Store buffer at 4°C.

002001-2626960

ACM Media		
NaCl	(Sigma S-5886)	0.290 g
KCl	(Sigma P-5405)	0.011 g
CaCl ₂ -2H ₂ O	(Sigma C-7902)	0.002 g
NaHCO ₃	(Sigma S-5761)	0.105 g
Na Lactate	(Sigma L-4263)	7 μ l
Pyruvate stock		1 ml
BME amino acids	(Sigma B-6766)	1 ml
MEM amino acids	(Sigma M-7145)	0.5 ml
L-Glutamine	(Sigma G-5763)	7.3 mg
Pen/Strep	(Sigma P-3539)	0.5 μ l
BSA fraction V	(Sigma A-4503)	150 g
Embryo transfer H ₂ O	(Sigma W-1503)	enough to make final volume 50 ml

- 15

Pyruvate Stock		
Pyruvic Acid	(Sigma P-2256)	2.2 mg
Embryo transfer H ₂ O	(Sigma W-1503)	1 ml

Label and store at 20°C in 1-ml aliquots

- 20

Ionomycin		
Ionomycin	(Calbiochem 407952 or (Sigma I-0634)	1 mg
Dimethyl Sulfoxide	(Sigma D-8799)	267.6 μ l

- 25

Z1

- TL Hepes + 1 mg/ml BSA (fraction V), pH to 7.2-7.4.
- Filter, label and store at 4°C in a capped container.

5	DMAP 200 mM (100X stock)		
	DMAP	(Sigma D-2629)	1 g
	PBS	(Gibco 21600-051)	30 ml

- Heat in boiling water bath to dissolve DMAP.
- Aliquot 20 μ l into small eppendorf tubes, label and date.
- 10 - Store aliquots at -20°C.

Mouse Fetal Fibroblasts Feeder Layers

- 15 Mouse fetal fibroblasts are gamma irradiated for five minutes and plated at 1×10^6 cells per ml of ALPHA-MEM culture media. Leave overnight or until cells are plated and change media to desired culture media.

	ALPHA-MEM Culture Media		
	ALPHA-MEM	(Gibco 12-169F)	500 ml
20	Fetal Calf Serum	(HyClone A-111-D)	50 ml
	Antibiotic/Antimicotic	(Sigma A-7292)	2 ml
	2-Mercaptoethanol	(Gibco 21985-023)	1.4 ml
	L-Glutamine Stock		5 ml
	Tylosine Tartrate	(Sigma G-5763)	0.5 ml

25	L-Glutamine Stock		
	L-Glutamine	(Sigma G-5763)	1.5 g
	DPBS		50 ml

- Filter and aliquot 5.5-6.0 ml in 15 ml tubes.
- 30 - Label and freeze on side.

Procedures - Oocyte Preparation

Bovine oocytes were stripped eighteen hours post maturation using 0.01% solution of hyaluronidase (1 mg/ml) contained in TL Hepes media. Afterward, the stripped oocytes are rinsed using HECM Hepes or TL Hepes. The resultant stripped, 5 rinsed oocytes are then stored or used directly for activation. Storage can be effected, e.g, in ACM at 37°C and five percent CO₂ until activation. Preferably, the ACM is equilibrated at 37°C and five percent CO₂ for about two to three hours before usage for oocyte storage.

Oocyte Activation

10 An appropriate activation protocol is used that results in the production of embryos having a discernible trophectoderm and inner cell mass. As previously disclosed, various methods can be used.

In particular, the inventors elected to effect activation by placing oocytes (prepared as above) in Z1 media containing 5μM of ionomycin for four minutes. This 15 media was prepared by diluting 2μL of 5mM ionomycin in 2 ml of Z1 medium.

Afterward, the oocytes were washed using HECM Hepes, and are then incubated in DMAP/ACM medium for three to four hours. This medium was prepared by dilution of 5 μL of 200 mM DMAP in 500 μl of ACM, with ACM/DMAP preferably being equilibrated at 37°C and five percent CO₂ in air for two to three hours prior to usage.

20 After incubation in DMAP/ACM, oocytes were washed four times in HECM Hepes. The washed oocytes were then placed in ACM on a mouse fibroblast feeder layer prepared as described above. The ACM media was again equilibrated at 37°C and five percent CO₂ in air for two to three hours prior to use.

This resulted in the production of blastocysts having a discernible trophectoderm 25 and inner cell mass (See Figures 1 through 10). Seven to nine days post activation, the blastocysts were dissected using 30 gauge/1 inch needles and placed on mouse fetal fibroblast feeder layers in ALPHA-MEM tissue culture medium. The cells were incubated thereon at 37°C and five percent CO₂ for one week.

The medium was changed every two to three days following said week of 30 incubation.

The cells were passaged onto new feeder layers manually. This was effected by culturing the colonies and pipetting directly the pieces onto new feeder layers. This procedure can be repeated by change of medium and repeated passaging indefinitely to produce pluripotent cells that give rise to differentiated cells. The efficacy of the described methods is substantiated by Figures 1 through 10. In particular, Figure 10 shows a pluripotent cell colony produced from a blastocyst produced by gynogenetic (parthenogenic) activation as described above, resulted in a pluripotent (stem cell) colony with differentiated cells being observed at the edge of the colony.

EXAMPLE 2

Production of Parthogenic Primate Primordial Stem Cells (PPSCs)

Materials and Methods

1- Cynomolgous Monkey (*Macaca fascicularis*) were superovulated using a single injection of 1000 IU of pregnant mare's serum gonadotrophin (PMSG) and 500 IU of human chorionic gonadotrophin (hCG) four days later.

2- Ovaries were retrieved by laparotomy and oocytes dissected from the follicles and placed in maturation media 36 to 48 hrs after (hCG). Maturation media consisted of medium-199 (Gibco BRL) with Earle's balanced salt solution supplemented with 20% fetal bovine serum, 10 IU/ml of PMSG, 10 IU/ml of hCG, 0.05 mg/ml of penicillin G and 0.075 mg/ml of streptomycin sulfate (Hong, 1999).

3- Oocyte activation

After 40 hrs in maturation, metaphase II eggs were placed in 10 micromoles of Ionomycin followed incubation in 200 mM 6-DMAP (dimethylaminopurine) for 3 to 4 hrs.

4- Embryo culture. Commercially available embryo culture media 'Cooks' was used (modified SOF). Embryos were cultured with a co-culture of mitotically inactivated mouse embryonic fibroblasts as feeder layer.

5 5- Isolation of inner cell mass

- a- Upon development to blastocyst, embryos were placed in a buffered solution of 0.3% pronase for 2 minutes to digest zona pellucida
- b- Blastocysts were then rinsed in buffered solution and moved to solution of G1 culture media and polyclonal antibodies (antihuman whole serum) 1:3 dilution for 30 minutes.
- c- Embryos were rinsed 5 times in a buffered solution.
- d- Embryos were moved into a solution of G1 culture media and guinea pig complement 1:3 dilution for 30 minutes.
- e- Remaining of the embryos (dead trophoblast cells and ICM) were rinsed 5 times in buffered solution the Inner Cell Mass (ICM) was isolated and placed on top of a mouse embryonic fibroblast feeder layer for isolation and growth of Primordial Stem Cells (PSC's).

Results

We have obtained 450 eggs total, after maturation, 224 were still at germinal vesicle stage (GV = no maturation), 79 were dead, 56 were at metaphase one (MI) and 91 at metaphase two (MII).

We have parthenogenically activated all of them. As expected, there was no cleavage on the GV group, 32% cleavage on the MI and 57% on the MII. When put in culture, 7 embryos developed to the blastocyst stage (See Figure 11).

After attempting to establish ES-like culture cells, four Inner cell masses attached nicely one differentiated immediately, and out of the three remaining, one cell line was obtained. This cell line is called Cyno 1 (Fig. 12). This cell line before and after immunosurgery is shown in Figures 12 and 13 . Figure 14 shows the Cyno 1 cell line five days after plating.

Figure 15 shows the Cyno 1 cell line growing on top of a mouse fibroblast feeder layer. These cells show typical morphology of pluripotent-embryonic-cells such as small nuclear cytoplasmic ratio and the presence of cytoplasmic granules.

These cells were maintained in an undifferentiated state for a period of 5 months. This is evidenced by screening of such cells after prolonged culturing for the expression of a cell marker characteristic of undifferentiated cells, Alkaline Phosphatase. As expected, cells were positive on passage 3 and on passage 5.

The fact that these cells maintain their pluripotency is also shown by their spontaneous differentiation into many differentiated cell types after being placed in 10 tissue culture in the absence of a feeder layer. In the days following, the cells were observed to differentiate into cuboidal epithelium, fibroblasts, beating myocardial cells and other cells. Two colonies of beating myocardial cells were observed in one well of a 4-well tissue culture plate.

To determine whether differentiated cells of various somatic cell lineages were 15 observed from the differentiating PPSCs, we extracted mRNA from differentiated cell cultures, performed RT-PCR, using human sequence primers specific for various differentiated cell types. As shown in Figure 16, transcripts of a predicted size for the mesodermally-derived transcripts brachyury and skeletal muscle myosin heavy polypeptide 2 were observed. The transcript sonic hedgehog essential for endoderm 20 development was observed. In addition, the neuron-specific ectoderm marker enolase was observed as well as keratin (not shown) as markers of ectodermally derived cells. These PCR products were not observed in the mouse feeder layer controls or in the absence of reverse transcriptase.

To establish that the imprinting status of parthogenetic PPSCs is different than 25 that of di-parental PPSCs we looked at the expression of several imprinted genes. Genes that are mono-allelically expressed from the paternal allele, would not be expected to be expressed in parthogenetic cells, as these cells are derived exclusively from the maternal genome. The *Snrpn* gene is mono-allelically expressed from the paternal allele in mouse blastocyst inner cell mass [Szabo, PE and Mann, JR; *Genes &* 30 *Development* 9:3097-3108 (1995)]. We looked at the expression of this gene in the

5 In Figure 17, the expected size RT-PCR product for the *Snrpn* gene is 260 bp.

While the invention has been described with respect to certain specific embodiments, it will be appreciated that many modifications and changes thereof may be made by those skilled in the art without departing from the spirit of the invention. It is intended, therefore, by the appended claims to cover all modifications and changes that fall within the true spirit and scope of the invention.

WHAT IS CLAIMED IS:

1. A method for producing pluripotent (ES) cells that can be used to produce differentiated cells and tissues comprising:
 - (a) obtaining a haploid cell in metaphase II that comprises DNA derived from a single individual male or female, which optionally may be genetically modified;
 - (b) activating said haploid cell by a method selected from the group consisting of (1) conditions that do not result in second polar body extrusion; (2) conditions that provide for polar body extrusion but in the presence of an agent that inhibits polar body extrusion, and (3) conditions that prevent the initial cleavage, and culturing said activated cell to produce a gynogenetic or androgenetic embryo comprising a discernible trophectoderm and an inner cell mass;
 - (c) isolating said inner cell mass or cells therefrom and transferring said inner cell mass or cells to an *in vitro* media that inhibits differentiation of said inner cell mass derived therefrom; and
 - (d) culturing said inner cell mass cells or cells derived therefrom to maintain said cells in an undifferentiated pluripotent state.
2. The method of Claim 1, wherein the metaphase II cell is an oocyte or blastomere.
3. The method of Claim 2, wherein the haploid cell is a human, non-human primate, bovine, porcine, or ovine oocyte or blastomere.
4. The method of Claim 3, wherein the haploid DNA derived from a single individual is human, bovine, primate, ovine, or porcine.
5. The method of Claim 4, wherein the cell is a human or bovine oocyte and the haploid DNA is human DNA.

6. The method of Claim 1, where said activation conditions include the use of DMAP (phosphorylation inhibitor) or other compound that inhibits second polar body extrusion.
7. The method of Claim 1, wherein activation conditions include use of a compound that inhibits microfilament or protein production.
8. The method of Claim 7, wherein said compound is cycloheximide or cytochalasin B.
9. The method of Claim 1, wherein the haploid DNA is of a female origin.
10. The method of Claim 1, wherein haploid DNA is of male origin.
11. The method of Claim 1, wherein the haploid cells are human oocytes containing human male or female DNA.
12. The method of Claim 1, wherein said cultured cells of (d) are allowed to differentiate.
13. The method of Claim 1, wherein said cells are implanted at a desired site *in vivo* that is to be engrafted with cells or tissue.
14. The method of claim 13 wherein said cells are implanted in an immunocompromised non-human animal.
15. The method of Claim 13, wherein said site is a wound, a joint, muscle, bone, or the central nervous system.

16. The method of Claim 1, wherein the cell obtained by (d) is genetically

17. A method for producing pluripotent (ES) cells that can be used to

(i) producing a diploid cell by implantation of two haploid nuclei derived

(ii) gynogenetically or androgenetically activating said diploid metaphase

(iii) isolating said inner cell mass or cells therefrom and culturing said ICM

18. The method of Claim 17, wherein the diploid cell is a mammalian

19. The method of Claim 17, wherein the diploid cell is a mammalian

20. The method of Claim 19, wherein the haploid nuclei are human,

21. The method of Claim 19, wherein said male haploid nuclei are that of

22. The method of Claim 17, wherein the pluripotent cells obtained in step

23. The method of Claim 22, wherein said pluripotent cells are introduced

24. The method of Claim 22, wherein said *in vivo* site is bone, cartilage,

25. An improved method of cell or tissue therapy wherein the

26. Pluripotent cells derived from haploid cells of male or female origin.

27. The pluripotent cells of claim 26 which are primate pluripotent cells.

28. The pluripotent cells of claim 27 which are human pluripotent cells.

29. Differentiated cells derived from the pluripotent cells of Claim 25.

30. The differentiated cells of Claim 29 which are primate.

31. The differentiated cells of Claim 30 which are human.

32. The pluripotent cells of Claim 26 which are genetically modified by

33. Pluripotent cells produced by the method of Claim 1.

35. The pluripotent cells of claim 34 which are human.


37. The method of claim 36 wherein said method comprises exposing said cells to both different combinations and concentrations of growth factors.

38. The method of claim 36 which selects for growth factors and culturing conditions that induce the differentiation of said pluripotent cells into differentiated cells selected from the group consisting of neural cells, cardiac cells, bone cells, hematopoietic cells, red blood cells, cartilage, intestinal cells, retinal cells, corneal cells, esophageal cells, and stomach cells.

[illegible]

1030353 v1


FIGURE 1



(31-11)


[illegible]

FIGURE 2




(31-18)

FIGURE 3




(31-25)

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	



(32-1)

[illegible]

(32-3)




[illegible][illegible]

FIGURE 7




(32-12)

006937-10200

[illegible]

(35-6)


FIGURE 9



(35-8)

00697207-103700

FIGURE 10



(35-19)

00/2201-10200

09697397-109700




FIG. 11


[illegible]

FIG. 12




FIG. 13

1	##	Paul	##
2	##	Paul	##
3	##	Paul	##
4	##	Paul	##
5	##	Paul	##
6	##	Paul	##
7	##	Paul	##
8	##	Paul	##
9	##	Paul	##
10	##	Paul	##
11	##	Paul	##
12	##	Paul	##
13	##	Paul	##
14	##	Paul	##
15	##	Paul	##
16	##	Paul	##
17	##	Paul	##
18	##	Paul	##
19	##	Paul	##
20	##	Paul	##
21	##	Paul	##
22	##	Paul	##
23	##	Paul	##
24	##	Paul	##
25	##	Paul	##
26	##	Paul	##
27	##	Paul	##
28	##	Paul	##
29	##	Paul	##
30	##	Paul	##
31	##	Paul	##
32	##	Paul	##
33	##	Paul	##
34	##	Paul	##
35	##	Paul	##
36	##	Paul	##
37	##	Paul	##
38	##	Paul	##
39	##	Paul	##
40	##	Paul	##
41	##	Paul	##
42	##	Paul	##
43	##	Paul	##
44	##	Paul	##
45	##	Paul	##
46	##	Paul	##
47	##	Paul	##
48	##	Paul	##
49	##	Paul	##
50	##	Paul	##
51	##	Paul	##
52	##	Paul	##
53	##	Paul	##
54	##	Paul	##
55	##	Paul	##
56	##	Paul	##
57	##	Paul	##
58	##	Paul	##
59	##	Paul	##
60	##	Paul	##
61	##	Paul	##
62	##	Paul	##
63	##	Paul	##
64	##	Paul	##
65	##	Paul	##
66	##	Paul	##
67	##	Paul	##
68	##	Paul	##
69	##	Paul	##
70	##	Paul	##
71	##	Paul	##
72	##	Paul	##
73	##	Paul	##
74	##	Paul	##
75	##	Paul	##
76	##	Paul	##
77	##	Paul	##
78	##	Paul	##
79	##	Paul	##
80	##	Paul	##
81	##	Paul	##
82	##	Paul	##
83	##	Paul	##
84	##	Paul	##
85	##	Paul	##
86	##	Paul	##
87	##	Paul	##
88	##	Paul	##
89	##	Paul	##
90	##	Paul	##
91	##	Paul	##
92	##	Paul	##
93	##	Paul	##
94	##	Paul	##
95	##	Paul	##
96	##	Paul	##
97	##	Paul	##
98	##	Paul	##
99	##	Paul	##
100	##	Paul	##




FIG. 14


[illegible]

FIG. 15




Figure 16. RT-PCR results demonstrating differentiation of multiple somatic cell types in differentiating PPSCs. Brachy: Brachyury (T) protein, MYH2: Skeletal myosin Heavy Polypeptide 2, Enolase: Human neuron-specific Enolase 2, SHH: Human homolog of Sonic Hedgehog.

260 bp 

— 453 bp
— 341
— 258
— 158

Figure 17. RT-PCR for snrpn in PPSCs.

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

Attorney's Docket No.

23523-0174

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND

USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES

the specification of which

(check one)



is attached hereto;



was filed on _____ as

Application No. _____

and was amended on _____;
(if applicable)

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code §119 and/or §365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES_ NO_
			YES_ NO_

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

APPLICATION SERIAL NO.	FILING DATE
60/161,987	October 28, 1999

I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (patented, pending, abandoned)

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

Robin L. Teskin (Reg. No. 35,030)
Bonnie Weiss (Reg. No. 43,255)
Milan Vinnola (Reg. No. 45,979)

Samir Elamrani (Reg. No. 43,601)
Michelle S. Marks (Reg. No. 41,971)

and: _____

Address all correspondence to:

SHAW PITTMAN
Attn: Technology/Patents
2300 N Street, N.W.
Washington, D.C. 20037-1128

Address all telephone calls to: Robin L. Teskin at (202) 663-8000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR		SIGNATURE		DATE	
James M. Robl					
RESIDENCE			CITIZENSHIP		
Belchertown, Massachusetts, U.S.A.			U.S.A.		
POST OFFICE ADDRESS					
196 Old Enfield, Belchertown, Massachusetts 01007 U.S.A.					
FULL NAME OF SECOND JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
Jose Cibelli					
RESIDENCE			CITIZENSHIP		
Amherst, Massachusetts, U.S.A.			U.S.A.		
POST OFFICE ADDRESS					
166 Village Park, Amherst, Massachusetts 01002 U.S.A.					
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
Amy Burnside					
RESIDENCE			CITIZENSHIP		
Florence, Massachusetts, U.S.A.			U.S.A.		
POST OFFICE ADDRESS					
400 Bridge Road, Florence, Massachusetts 01062 U.S.A.					
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
RESIDENCE			CITIZENSHIP		
POST OFFICE ADDRESS					
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
RESIDENCE			CITIZENSHIP		
POST OFFICE ADDRESS					
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
RESIDENCE			CITIZENSHIP		
POST OFFICE ADDRESS					
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
RESIDENCE			CITIZENSHIP		
POST OFFICE ADDRESS					
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE		DATE	
RESIDENCE			CITIZENSHIP		
POST OFFICE ADDRESS					